BioSpace News Archive

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a United States-based leading medical cannabis company, announced today that CEO Kim Rivers is scheduled to participate in the 9th Annual Gateway Conference,

The Alzheimer’s Association announced that it has been selected by the Centers for Disease Control and Prevention as the BOLD Public Health Center of Excellence on Dementia Risk Reduction.

A novel study in AACC’s Clinical Chemistry journal shows that a new test for SARS-CoV-2 viral proteins known as antigens could determine which COVID-19 patients are most likely to become critically ill.

Rondo-Pak, LLC, a Joint Venture with Körber Pharma group, has named Bob Reilley as its President and Chief Operating Officer.

Eisai Co., Ltd. announced today that it will take over by transfer the manufacturing and marketing approval of Parkinson’s disease treatment Equfina 50mg TABLETS (safinamide mesilate, “Equfina”) in Japan from Meiji Seika Pharma Co., Ltd., effective September 23, 2020.

Aptorum Group Limited, a biopharmaceutical company focused on novel therapeutics including the development of next-generation approach therapeutics targeting antimicrobial resistance, announced President and Executive Director, Mr. Darren Lui, will share insight into the company’s recent developments and upcoming milestones at an investor webinar and the Wall Street Investor Forum on Thursday, September 10, 2020.

Invivoscribe, Inc., an industry pioneer in developing and commercializing diagnostic products and reagents for hematological malignancies, announced key members of the leadership team hired to direct Invivoscribe Therapeutics, Inc., its fully integrated drug development engine.

Results from pivotal phase 2/3 study met co-primary endpoints for improvement in trough plasminogen activity levels and reduction in lesion size

RECORLEV® (levoketoconazole) was Generally Well Tolerated with a Safety and Tolerability Profile Comparable to the Profile Observed in the Phase 3 SONICS Study

Metrion Biosciences Limited, the specialist ion channel CRO and drug discovery company, announced it has significantly enhanced its global business development capabilities, with additional resources now committed to support key regions in the USA, Europe and Japan.